Evidence map›Paper›PMID 23806666›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2013

Improving molecular tools for global surveillance of measles virus.

Bettina Bankamp, Lauren A Byrd-Leotis, Elena N Lopareva, Gibson K S Woo, Chunyu Liu, Youngmee Jee, Hinda Ahmed, Wilina W Lim, Nalini Ramamurty, Mick N Mulders and 3 more

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Maintenance of Measles Elimination Status in the United States for 20 Years Despite Increasing Challenges.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Diagnostic challenges and pockets of susceptibility identified during a measles outbreak, Luxembourg, 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 6 countries.

Bettina BankampMeasles, Mumps, Rubella and Herpes Virus Laboratory Branch, Division of Viral Diseases, Centers for Disease Control and Prevention, MS C-22, 1600 Clifton Road, Atlanta, GA 30333, USA. bbankamp@cdc.gov
Lauren A Byrd-Leotis
Elena N Lopareva
Gibson K S Woo
Chunyu Liu
Youngmee Jee
Hinda Ahmed
Wilina W Lim
Nalini Ramamurty
Mick N Mulders
David Featherstone
William J Bellini
Paul A Rota
Centers for Disease Control and Prevention · USDepartment of Health · CNWorld Health Organization · CHWorld Health Organization Regional Office for South-East Asia · INWorld Health Organization Regional Office for the Eastern Mediterranean · EGWorld Health Organization Regional Office for the Western Pacific · PH

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundThe genetic characterization of wild-type measles viruses plays an important role in the description of viral transmission pathways and the verification of measles elimination. The 450 nucleotides that encode the carboxyl-terminus of the nucleoprotein (N-450) are routinely sequenced for genotype analysis.

objectivesThe objectives of this study were to develop improved primers and controls for RT-PCR reactions used for genotyping of measles samples and to develop a method to provide a convenient, safe, and inexpensive means to distribute measles RNA for RT-PCR assays and practice panels. STUDY

designA newly designed, genetically defined synthetic RNA and RNA isolated from cells infected with currently circulating genotypes were used to compare the sensitivity of primer pairs in RT-PCR and nested PCR. FTA® cards loaded with lysates of measles infected cells were tested for their ability to preserve viral RNA and destroy virus infectivity.

resultsA new primer pair, MeV216/MeV214, was able to amplify N-450 from viruses representing 10 currently circulating genotypes and a genotype A vaccine strain and demonstrated 100-fold increased sensitivity compared to the previously used primer set. A nested PCR assay further increased the sensitivity of detection from patient samples. A synthetic positive control RNA was developed that produced PCR products that are distinguishable by size from PCR products amplified from clinical samples. FTA® cards completely inactivated measles virus and stabilized RNA for at least six months.

conclusionsThese improved molecular tools will advance molecular characterization of circulating measles viruses globally and provide enhanced quality control measures.

Indexed as

DNA PrimersEpidemiological MonitoringGenotypeGlobal HealthHumansMeaslesMeasles virusMolecular Diagnostic TechniquesMolecular EpidemiologyReference StandardsReverse Transcriptase Polymerase Chain ReactionRNA, ViralSensitivity and SpecificityDNA PrimersRNA, ViralCDCCenters for Disease Control and PreventioncpeCtcytopathic effectFTA(®) cardsGenotypingLabNetMeaslesmeasles virusMeVMolecular diagnosticsntnucleotidesroom temperatureRTthreshold cycleWHOWHO Measles and Rubella Laboratory NetworkWorld Health Organization

Identifiers

PMID23806666
PMCPMC5751696
OpenAlexW2118815594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.